|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Demographic** | **Arm 1**(n=257) | **Arm 2**(n=263) | **Arm 3**(n=259) | **Total**(n=779) |
| Age, years | 65 (59-70) | 62 (54-68) | 64 (55-69) | 64 (56-69) |
| ECOG performance status |  |  |  |  |
|  0 | 105 (41) | 113 (43) | 93 (36) | 311 (40) |
|  1 | 122 (48) | 123 (47) | 135 (52) | 380 (49) |
|  2 | 28 (11) | 27 (10) | 31 (12) | 86 (11) |
| Histological type |  |  |  |  |
|  High-grade serous carcinoma | 199 (77) | 185 (70) | 194 (75) | 578 (74) |
|  Low-grade serous carcinoma | 4 (2) | 7 (3) | 3 (1) | 14 (2) |
|  Serous (no grade specified) carcinoma | 7 (3) | 8 (3) | 7 (3) | 22 (3) |
|  Clear cell | 4 (2) | 3 (1) | 5 (2) | 12 (2) |
|  Endometrioid | 1 (<1) | 2 (1) | 2 (1) | 5 (1) |
|  Mucinous | 0 | 3 (1) | 2 (1) | 5 (1) |
|  Mixed | 2 (1) | 3 (1) | 3 (1) | 8 (1) |
|  Other | 40 (16) | 52 (20) | 43 (17) | 135 (17) |
| FIGO stage |  |  |  |  |
|  IC or IIA | 1 (<1) | 1 (<1) | 2 (1) | 4 (1) |
|  IIB or IIC | 3 (1) | 4 (2) | 1 (<1) | 8 (1) |
|  IIIA or IIIB | 6 (2) | 13 (5) | 15 (6) | 34 (4) |
|  IIIC | 177 (69) | 171 (65) | 159 (61) | 507 (65) |
|  IV | 70 (27) | 74 (28) | 82 (32) | 226 (29) |
| Number of NACT cycles received |  |  |  |  |
|  ≤4 cycles | 172 (67) | 191 (73) | 184 (71) | 547 (70) |
|  5/6 cycles | 25 (10) | 27 (10) | 17 (7) | 69 (11) |
|  *Surgery not performed* | *40 (16)* | *30 (11)* | *42 (16)* | *112 (14)* |
|  *Surgery data missing* | *20 (8)* | *15 (6)* | *16 (6)* | *51 (7)* |

**Table 1. Demographic data for patients undergoing neoadjuvant chemotherapy followed by delayed primary surgery.** Data are presented as median (IQR) or number (%). Key: ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynaecology and Obstetrics; NACT, neoadjuvant chemotherapy; n, number. Arm 1 was three weekly carboplatin and paclitaxel, Arm 2 was three weekly carboplatin and weekly paclitaxel, Arm 3 was weekly carboplatin and weekly paclitaxel. An ECOG performance status of 0 equates to fully active, able to carry on all pre-disease performance without restriction; 1 equates to restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; and 2 equates to ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.

|  |  |  |
| --- | --- | --- |
| **RECIST v1**.**1 response** | **Trial Arms** | **Total** |
| **Arm 1** | **Arm 2** | **Arm 3** |
| Complete response | 8 (4) | 6 (3) | 7 (4) | 21 (4) |
| Partial response | 102 (56) | 119 (61) | 106 (57) | 327 (58) |
| Stable disease | 61 (34) | 60 (31) | 62 (33) | 183 (32) |
| Progressive disease | 11 (6) | 10 (5) | 12 (6) | 33 (6) |
| Non-measurable disease at baseline | 29 | 27 | 29 | 85 |
| **Total (including non-measurable)** | **211** | **222** | **216** | **649** |
| **GCIG CA125 response\*** | **Trial Arms** | **Total** |
| **Arm 1** | **Arm 2** | **Arm 3** |
| Yes | 198 (83) | 204 (84) | 208 (85) | 610 (84) |
| No | 42 (18) | 39 (16) | 36 (15) | 117 (16) |
| **Total** | **240** | **243** | **244** | **727** |

**Table 2. RECIST v1**.**1 and GCIG CA125 response to neoadjuvant chemotherapy.** Data presented as number (%) where % is column percentage (*Non-measurable disease at baseline* not included in denominator for RECIST v1.1 response). Arm 1 was three weekly carboplatin and paclitaxel, Arm 2 was three weekly carboplatin and weekly paclitaxel, Arm 3 was weekly carboplatin and weekly paclitaxel. Key: \*All assessable patients had a pre-treatment CA125 of twice the upper limit of normal range.

|  |  |
| --- | --- |
|  | **GCIG CA125 response** |
| **Yes**  | **No** | **Missing** | **Total**  |
| **RECIST v1**.**1 response** | Complete response | 18 | 1 | 2 | 21 |
| Partial response | 287 | 23 | 17 | 327 |
| Stable disease | 127 | 51 | 5 | 183 |
| Progressive disease | 21 | 6 | 6 | 33 |
| Non-measurable disease at baseline  | 66 | 13 | 6 | 85 |
| *Missing* | *91* | *23* | *0* | *114* |
| **Total (including missing)** | **610** | **117** | **36** | **763** |

**Table 3. RECIST v1**.**1 and GCIG CA125 response to neoadjuvant chemotherapy.** Data are presented as number.

|  |  |  |
| --- | --- | --- |
| **Outcome of cytoreductive surgery** | **RECIST v1**.**1 response** | **GCIG CA125 response** |
| **CR** | **PR** | **SD** | **PD** | **Total †** | **Yes** | **No** | **Total** |
| Residual disease: 0 cm (complete/R0) | 15 (75) | 172 (55) | 73 (42) | 14 (48) | 274 (51) | 290 (50) | 30 (30) | 320 (47) |
| Residual disease: ≤1 cm (optimal) | 3 (15) | 77 (24) | 44 (26) | 3 (10) | 127 (24) | 145 (25) | 19 (19) | 164 (24) |
| Residual disease: >1 cm (suboptimal) | 1 (5) | 33 (10) | 24 (14) | 2 (7) | 60 (11) | 72 (13) | 10 (10) | 82 (12) |
| Inoperable (open and close surgery) | 0 | 5 (2) | 3 (2) | 0 | 8 (1) | 8 (1) | 2 (2) | 10 (1) |
| Surgery not performed | 1 (5)\* | 28 (9) | 28 (16) | 10 (34) | 67 (13) | 61 (11) | 40 (40) | 101 (15) |
| *Surgery data missing* | *1* | *12* | *11* | *4* | *28* | *34* | *16* | *50* |
| **Total (including missing)** | **21** | **327** | **183** | **33** | **564** | **610** | **117** | **727** |

**Table 4. Outcome of cytoreductive surgery following neoadjuvant chemotherapy according to RECIST v1**.**1 and GCIG CA125 response.** Data are presented as number (%) where % is column percentage (*Surgery data missing* not included in denominator). Key: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. \*Reason stated by investigator as “clinical decision”; † Patients with RECIST v1.1 non-measurable disease were not included (n=85).